GNF SymAtlas + NCI-60 cancer cell lines, human (Su, 2004; Ross, 2000)
Gene | Promoter | Pearson corr. coef. | P-value | Plot |
---|---|---|---|---|
CHD1 | hg19_v2_chr5_-_98262240_98262240 | 0.30 | 5.7e-06 | Click! |
SIN3A | hg19_v2_chr15_-_75743991_75744011 | 0.20 | 2.4e-03 | Click! |
Promoter | Log-likelihood | Transcript | Gene | Gene Info |
---|---|---|---|---|
chr7_-_140178775 Show fit | 28.70 |
ENST00000474576.1
ENST00000473444.1 ENST00000471104.1 |
makorin ring finger protein 1 |
|
chr13_-_77900814 Show fit | 23.91 |
ENST00000544440.2
|
MYC binding protein 2, E3 ubiquitin protein ligase |
|
chr2_+_87140935 Show fit | 23.68 |
ENST00000398193.3
|
RANBP2-like and GRIP domain containing 1 |
|
chr3_-_18466787 Show fit | 23.03 |
ENST00000338745.6
ENST00000450898.1 |
SATB homeobox 1 |
|
chr13_-_77901177 Show fit | 22.16 |
ENST00000407578.2
ENST00000357337.6 ENST00000360084.5 |
MYC binding protein 2, E3 ubiquitin protein ligase |
|
chr17_+_36861735 Show fit | 20.74 |
ENST00000378137.5
ENST00000325718.7 |
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 6 |
|
chr11_-_46142948 Show fit | 19.48 |
ENST00000257821.4
|
PHD finger protein 21A |
|
chr16_-_58231782 Show fit | 19.45 |
ENST00000565188.1
ENST00000262506.3 |
casein kinase 2, alpha prime polypeptide |
|
chr8_+_56014949 Show fit | 18.48 |
ENST00000327381.6
|
XK, Kell blood group complex subunit-related family, member 4 |
|
chr20_+_57466629 Show fit | 18.30 |
ENST00000371081.1
ENST00000338783.6 |
GNAS complex locus |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.3 | 66.8 | GO:0000209 | protein polyubiquitination(GO:0000209) |
0.5 | 66.4 | GO:0006333 | chromatin assembly or disassembly(GO:0006333) |
1.6 | 45.1 | GO:0000042 | protein targeting to Golgi(GO:0000042) |
11.2 | 44.9 | GO:0071894 | histone H2B conserved C-terminal lysine ubiquitination(GO:0071894) |
2.5 | 40.2 | GO:0043374 | CD8-positive, alpha-beta T cell differentiation(GO:0043374) |
0.5 | 36.8 | GO:0006369 | termination of RNA polymerase II transcription(GO:0006369) |
0.4 | 36.4 | GO:0007286 | spermatid development(GO:0007286) |
0.8 | 31.6 | GO:0007214 | gamma-aminobutyric acid signaling pathway(GO:0007214) |
0.2 | 31.3 | GO:0006325 | chromatin organization(GO:0006325) |
1.0 | 31.2 | GO:0048268 | clathrin coat assembly(GO:0048268) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.4 | 163.5 | GO:0016607 | nuclear speck(GO:0016607) |
0.1 | 108.4 | GO:0005654 | nucleoplasm(GO:0005654) |
0.3 | 103.4 | GO:0000785 | chromatin(GO:0000785) |
0.0 | 88.5 | GO:0005634 | nucleus(GO:0005634) |
0.1 | 76.3 | GO:0005730 | nucleolus(GO:0005730) |
0.3 | 57.7 | GO:0005694 | chromosome(GO:0005694) |
0.5 | 57.6 | GO:0016363 | nuclear matrix(GO:0016363) |
0.3 | 53.9 | GO:0000793 | condensed chromosome(GO:0000793) |
0.2 | 51.0 | GO:0000151 | ubiquitin ligase complex(GO:0000151) |
0.4 | 49.3 | GO:0034705 | voltage-gated potassium channel complex(GO:0008076) potassium channel complex(GO:0034705) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.1 | 169.3 | GO:0003677 | DNA binding(GO:0003677) |
0.5 | 88.6 | GO:0061659 | ubiquitin-like protein ligase activity(GO:0061659) |
1.5 | 87.9 | GO:0004407 | histone deacetylase activity(GO:0004407) |
1.9 | 56.7 | GO:0000993 | RNA polymerase II core binding(GO:0000993) |
0.2 | 50.2 | GO:0005096 | GTPase activator activity(GO:0005096) |
1.3 | 47.1 | GO:0031624 | ubiquitin conjugating enzyme binding(GO:0031624) |
0.5 | 42.1 | GO:0101005 | thiol-dependent ubiquitinyl hydrolase activity(GO:0036459) ubiquitinyl hydrolase activity(GO:0101005) |
0.5 | 37.6 | GO:0042393 | histone binding(GO:0042393) |
0.4 | 36.6 | GO:0004386 | helicase activity(GO:0004386) |
2.0 | 36.1 | GO:0019992 | diacylglycerol binding(GO:0019992) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.7 | 60.1 | PID AR TF PATHWAY | Regulation of Androgen receptor activity |
1.0 | 56.0 | PID TCR CALCIUM PATHWAY | Calcium signaling in the CD4+ TCR pathway |
0.7 | 41.2 | PID BCR 5PATHWAY | BCR signaling pathway |
0.4 | 35.8 | PID E2F PATHWAY | E2F transcription factor network |
0.8 | 35.0 | PID RAS PATHWAY | Regulation of Ras family activation |
1.5 | 33.4 | PID TCR RAS PATHWAY | Ras signaling in the CD4+ TCR pathway |
0.4 | 33.3 | PID NOTCH PATHWAY | Notch signaling pathway |
0.9 | 33.2 | PID NFKAPPAB ATYPICAL PATHWAY | Atypical NF-kappaB pathway |
0.8 | 32.7 | PID GMCSF PATHWAY | GMCSF-mediated signaling events |
0.8 | 30.1 | PID HDAC CLASSII PATHWAY | Signaling events mediated by HDAC Class II |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.3 | 80.3 | REACTOME ANTIGEN PROCESSING UBIQUITINATION PROTEASOME DEGRADATION | Genes involved in Antigen processing: Ubiquitination & Proteasome degradation |
1.2 | 53.2 | REACTOME RAP1 SIGNALLING | Genes involved in Rap1 signalling |
0.7 | 38.6 | REACTOME G1 PHASE | Genes involved in G1 Phase |
1.0 | 37.8 | REACTOME SIGNALING BY FGFR1 FUSION MUTANTS | Genes involved in Signaling by FGFR1 fusion mutants |
1.2 | 34.7 | REACTOME TRAFFICKING OF GLUR2 CONTAINING AMPA RECEPTORS | Genes involved in Trafficking of GluR2-containing AMPA receptors |
1.1 | 30.7 | REACTOME CIRCADIAN REPRESSION OF EXPRESSION BY REV ERBA | Genes involved in Circadian Repression of Expression by REV-ERBA |
0.6 | 30.1 | REACTOME MYOGENESIS | Genes involved in Myogenesis |
0.4 | 29.6 | REACTOME MITOTIC PROMETAPHASE | Genes involved in Mitotic Prometaphase |
0.7 | 28.8 | REACTOME ANTIGEN ACTIVATES B CELL RECEPTOR LEADING TO GENERATION OF SECOND MESSENGERS | Genes involved in Antigen Activates B Cell Receptor Leading to Generation of Second Messengers |
0.6 | 27.7 | REACTOME VOLTAGE GATED POTASSIUM CHANNELS | Genes involved in Voltage gated Potassium channels |